What is the Fiscal Year for enGene?
Date: November 14, 2026
enGene's current fiscal year starts on November 1, 2026, and ends on October 31, 2027. Their current quarter is Q1, which ends on January 31, 2027.
Current Fiscal Year Overview
Fiscal Year Start
November 1, 2026
Fiscal Year End
October 31, 2027
Current Quarter
Q1
Current Quarter End
January 31, 2027
Quarterly Breakdown
Q1
Nov 1, 2026 – Jan 31, 2027
Q2
Feb 1, 2027 – Apr 30, 2027
Q3
May 1, 2027 – Jul 31, 2027
Q4
Aug 1, 2027 – Oct 31, 2027
Company Information
Headquarters
Boston, Massachusetts
Industry
Biotechnology Research
Stock Symbol
ENGN
Website
https://engene.comDescription
enGene (Nasdaq: ENGN) is a clinical-stage biotechnology company mainstreaming non-viral genetic medicines that can be delivered locally to the site of disease—starting with non-muscle invasive bladder cancer (NMIBC) and expanding beyond. Founded in Canada, with a United States headquarters located in Boston, we are developing innovative solutions with the goal of reducing treatment burden and improving patient outcomes. To learn more about enGene visit our website: enGene.com. We are currently enrolling select patients with NMIBC in our LEGEND clinical trial. We have sites in the United States, Canada, Europe and the Asia-Pacific region. For more information, please visit TheLegendStudy.com.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like enGene and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.